The commission aims to undercut large PBMs' use of its previously stated concerns as support for their lobbying against state and federal industry reforms, but the PBM trade association remains undeterred by the action.
The Federal Trade Commission doesn’t want to hinder state and federal government efforts to reform pharmacy benefit managers as it continues its investigation of possible anti-competitive business practices in the industry.
The FTC is backing away from past policy statements expressing concern with mandatory PBM disclosures.
With that in mind, the commission unanimously adopted a position statement 20 July that “cautions against reliance on certain...
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.
